Europe's Biotechs Gathering Steam With Filgotinib Filing

Galapagos is another step closer to commercializing its products with its lead candidate, filgotinib, now under the gaze of EU regulators.

Engine
Getting a drug to market is a complex business • Source: Shutterstock

Every so often, one of Europe’s biotechs finds itself on the brink of becoming a fully integrated biopharmaceutical company, an event that this time around features Galapagos NV.

Galapagos and its US partner, Gilead Sciences Inc., announced on 15 August that the marketing submission for their oral...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip